CareFusion, Terumo Sign Distribution Agreement For IV Catheters

Eight-Year Exclusive Agreement for CareFusion to Market SurFlash® Catheters in U.S. Acute Care Segment

Jan 29, 2014

SAN DIEGO, CA, Jan. 29, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, and Terumo Corporation, the largest medical technology company in Japan, today announced an exclusive, eight-year agreement for CareFusion to co-brand, market and distribute Terumo's SurFlash® line of safety peripheral IV catheters for the acute care segment across the United States.

The agreement includes both SurFlash and SurFlash Plus Safety IV Catheters, which are proven to improve the success of catheter placement on the first attempt by an average of 20 percent. The higher success rate for first placement can potentially enhance the patient experience, reduce wasted catheters and save clinician time, all of which reduce costs for the hospital.

"This agreement broadens our vascular access portfolio and adds a critical link to enable CareFusion to provide an expanded range of products," said Vivek Jain, president of Procedural Solutions for CareFusion. "From skin preparation to needle-free connectors and IV sets, the SurFlash brand builds on our established leadership of clinically differentiated products for vascular access procedures. We are proud to collaborate with a global medical technology leader like Terumo."

Terumo's agreement with CareFusion will focus solely on the U.S. acute care hospital market.

"CareFusion's world-class clinical and commercial presence in acute care infusion will accelerate the U.S. market impact of these safety products faster than Terumo might otherwise achieve," said Hideo Arase, president and CEO of Terumo Medical Corporation and Terumo Americas Holding, Inc. "The synergies are clear."

SurFlash and SurFlash Plus Safety IV Catheters have a passive safety technology that completely encapsulates the needle reducing the risk of needle stick injuries and exposure to blood borne pathogens. The automatic engagement of this safety feature requires no intentional effort from the clinician, allowing for minimal technique change and faster adoption. These products are also the only catheters with the double-flash SurFlash feature that gives visual confirmation of when both the needle and catheter gain entry into a vessel, minimizing the risk for failed attempts.

The SurFlash Plus Safety IV Catheter also incorporates a proprietary blood control safety valve designed to minimize the risk of blood exposure between the removal of the needle and the attachment of the IV set. This helps create a cleaner access site and IV hub area to reduce the risk of physical and visual exposure to blood.

CareFusion will begin to market and distribute these products this month. Financial terms of the agreement were not disclosed.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Troy Kirkpatrick

858 617 2361
Email Troy

Back to News Releases